Abstract:Background: HIV-associated neurocognitive disorders (HAND) is hypothesized to be a result of myeloid cell-induced neuro-inflammation in the central nervous system that may be initiated in the periphery, but the contribution of peripheral T cells in HAND pathogenesis remains poorly understood. Methods: We assessed markers of T cell activation (HLA-DR + CD38+), immunosenescence (CD57 + CD28-), and immune-exhaustion (TIM-3, PD-1 and TIGIT) as well as monocyte subsets (classical, intermediate, and non-classical) by flow cytometry in peripheral blood derived from individuals with HIV on long-term stable anti-retroviral therapy (ART). Additionally, normalized neuropsychological (NP) composite test z-scores were obtained and regional brain volumes were assessed by magnetic resonance imaging (MRI). Relationships between proportions of immune phenotypes (of T-cells and monocytes), NP z-scores, and brain volumes were analyzed using Pearson correlations and multiple linear regression models. Results: Of N = 51 participants, 84.3% were male, 86.3% had undetectable HIV RNA < 50 copies/ml, median age was 52 [47, 57] years and median CD4 T cell count was 479 [376, 717] cells/uL. Higher CD4 T cells expressing PD-1 + and/or TIM-3 + were associated with lower executive function and working memory and higher CD8 T cells expressing PD-1+ and/or TIM-3+ were associated with reduced brain volumes in multiple regions (putamen, nucleus accumbens, cerebellar cortex, and subcortical gray matter). Furthermore, higher single or dual frequencies of PD-1 + and TIM-3 + expressing CD4 and CD8 T-cells correlated with higher CD16 + monocyte numbers. Conclusions: This study reinforces evidence that T cells, particularly those with immune exhaustion phenotypes, are associated with neurocognitive impairment and brain atrophy in people living with HIV on ART. Relationships revealed between T-cell immune exhaustion and inflammatory in CD16+ monocytes uncover interrelated cellular processes likely involved in the immunopathogenesis of HAND.

Future Directions for Diagnosis and Treatment

HIV-associated Dementia: New Insights into Disease Pathogenesis and Therapeutic Interventions.

Alzheimer's disease-like perturbations in HIV-mediated neuronal dysfunctions: understanding mechanisms and developing therapeutic strategies

Macrophages, Chemokines and Neuronal Injury in HIV-1-associated Dementia.

HIV-Proteins-Associated CNS Neurotoxicity, Their Mediators, and Alternative Treatments

Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders

A Look into Cellular and Molecular Pathology

Neuropathologic Findings in Elderly HIV-Positive Individuals

Unraveling the Mechanisms of Neurotoxicity in HIV Type 1-Associated Dementia: Inhibition of Neuronal Synaptic Transmission by Macrophage Secretory Products

HIV-related neurocognitive disorders: Diagnosis, Treatment, and Mental Health Implications: A Review

The HIV-1 Associated Dementia Complex

HIV-associated neurocognitive disorder: key implications of the microbiota-gut-brain axis

[Advances of immunological pathogenesis research in HIV related neurocognitive disorder].

A mouse model of HIV-associated neurocognitive disorders: a brain-behavior approach to discover disease mechanisms and novel treatments

HIV-1 Infected and Immune Competent Mononuclear Phagocytes Induce Quantitative Alterations in Neuronal Dendritic Arbor: Relevance for HIV-1-associated Dementia.

Multimodal Approach to Neurocognitive Function in People Living with HIV in the cART Era: A Comprehensive Review

Dynamics of peripheral T cell exhaustion and monocyte subpopulations in neurocognitive impairment and brain atrophy in chronic HIV infection

HIV-1 Infected Mononuclear Phagocyte Secretory Products Affect Neuronal Physiology Leading to Cellular Demise: Relevance for HIV-1-associated Dementia.

Intracellular CXCR4 Signaling, Neuronal Apoptosis and Neuropathogenic Mechanisms of HIV-1-associated Dementia

The Neuropathogenesis of Hiv-1 Infection

Suppression Of Inflammatory Neurotoxins By Highly Active Antiretroviral Therapy In Human Immunodeficiency Virus-Associated Dementia